315 related articles for article (PubMed ID: 28504193)
1. Global economic evaluations of rotavirus vaccines: A systematic review.
Kotirum S; Vutipongsatorn N; Kongpakwattana K; Hutubessy R; Chaiyakunapruk N
Vaccine; 2017 Jun; 35(26):3364-3386. PubMed ID: 28504193
[TBL] [Abstract][Full Text] [Related]
2. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.
Plosker GL
Pharmacoeconomics; 2011 Nov; 29(11):989-1009. PubMed ID: 21988293
[TBL] [Abstract][Full Text] [Related]
3. Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
Kim SY; Sweet S; Slichter D; Goldie SJ
BMC Public Health; 2010 May; 10():253. PubMed ID: 20470426
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of rotavirus vaccination cost-effectiveness in high income settings utilising dynamic transmission modelling techniques.
Jesudason T; Rodarte A; Tordrup D; Carias C; Chen YH
Vaccine; 2023 Aug; 41(36):5221-5232. PubMed ID: 37479614
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
Janko MM; Joffe J; Michael D; Earl L; Rosettie KL; Sparks GW; Albertson SB; Compton K; Pedroza Velandia P; Stafford L; Zheng P; Aravkin A; Kyu HH; Murray CJL; Weaver MR
Vaccine; 2022 Jun; 40(28):3903-3917. PubMed ID: 35643565
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of childhood rotavirus vaccination in Germany.
Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
[TBL] [Abstract][Full Text] [Related]
11. Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework.
Carvalho N; Jit M; Cox S; Yoong J; Hutubessy RCW
Pharmacoeconomics; 2018 Jan; 36(1):79-90. PubMed ID: 28905279
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.
Javanbakht M; Moradi-Lakeh M; Yaghoubi M; Esteghamati A; Mansour Ghanaie R; Mahmoudi S; Shamshiri AR; Zahraei SM; Baxter L; Shakerian S; Chaudhri I; Fleming JA; Munier A; Baradaran HR
Vaccine; 2015 May; 33 Suppl 1():A192-200. PubMed ID: 25919160
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluations of rotavirus immunization for developing countries: a review of the literature.
Tu HA; Woerdenbag HJ; Kane S; Rozenbaum MH; Li SC; Postma MJ
Expert Rev Vaccines; 2011 Jul; 10(7):1037-51. PubMed ID: 21806398
[TBL] [Abstract][Full Text] [Related]
14. Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies.
Hungerford D; Smith K; Tucker A; Iturriza-Gómara M; Vivancos R; McLeonard C; A Cunliffe N; French N
BMC Infect Dis; 2017 Aug; 17(1):569. PubMed ID: 28810833
[TBL] [Abstract][Full Text] [Related]
15. Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi.
Niyibitegeka F; Thavorncharoensap M; Riewpaiboon A; Youngkong S
Appl Health Econ Health Policy; 2022 Sep; 20(5):707-716. PubMed ID: 35469393
[TBL] [Abstract][Full Text] [Related]
16. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
[TBL] [Abstract][Full Text] [Related]
18. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
[TBL] [Abstract][Full Text] [Related]
20. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines.
Pecenka C; Debellut F; Bar-Zeev N; Anwari P; Nonvignon J; Shamsuzzaman M; Clark A
Vaccine; 2018 Nov; 36(49):7472-7478. PubMed ID: 30420039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
